Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, September 2000, p. 739-744, Vol. 7, No. 5
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Comparison of Five Serologic Tests for Diagnosis of
Acute Infections by Chlamydia pneumoniae
Kenneth
Persson1,* and
Jens
Boman2
Department of Clinical Microbiology,
Malmö University Hospital, S-205 02 Malmö,1 and Department of
Clinical Virology, The University Hospital of Umeå, S-901 85 Umeå,2 Sweden
Received 24 January 2000/Returned for modification 5 April
2000/Accepted 14 June 2000
Serology is often used to diagnose acute infections by
Chlamydia pneumoniae. In this study paired sera from
patients with acute respiratory tract infection during an epidemic of
C. pneumoniae infections were examined by five different
antibody tests. These tests were the complement fixation (CF) test, the
microimmunofluorescence (MIF) test, a recombinant enzyme immunoassay
(rEIA) (Medac) based on a recombinant lipopolysaccharide of chlamydia
and measuring antibodies to a common chlamydial antigen, and two tests
that utilize preparations of C. pneumoniae organisms, the
SeroCp-EIA (Savyon) (with preserved lipopolysaccharide) and the LOY-EIA
(Labsystems) (without this antigen). Both of the last two tests should
measure specific antibodies to C. pneumoniae, although
cross-reacting antibodies may also be detected by the SeroCp-EIA. Acute
infection of C. pneumoniae was serologically confirmed in
44% of the cases by at least two different tests. Using an expanded
"gold standard," i.e., the presence of significant reactions in at
least two tests, the sensitivity of the CF test was 69%, that of the
MIF test was 88%, that of the rEIA was 89%, that of the LOY-EIA was
96%, and that of the SeroCp-EIA was 92%. Specificity was high for all
methods, but adjustments of diagnostic criteria were made to several of the tests. The basis for these adjustments and supportive data are
presented. Infections of C. pneumoniae were detected in
patients from 8 to 83 years of age. Two peaks in the incidence of such infections were observed: one among young teenagers and a second in
adults 30 to 45 years of age, corresponding to parents of young teen-agers. The tests were equally sensitive in different age groups.
Reinfections seemed to be rare.
*
Corresponding author. Mailing address: Dept.
Clinical Microbiology, Malmö University Hospital, S-205 02 Malmö, Sweden. Phone: 46-40-331365. Fax: 46-40-337312. E-mail: Kenneth.Persson{at}mikrobiol.mas.lu.se.
Clinical and Diagnostic Laboratory Immunology, September 2000, p. 739-744, Vol. 7, No. 5
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Paldanius, M., Bloigu, A., Alho, M., Leinonen, M., Saikku, P.
(2005). Prevalence and Persistence of Chlamydia pneumoniae Antibodies in Healthy Laboratory Personnel in Finland. CVI
12: 654-659
[Abstract]
[Full Text]
-
Tenenbaum, T., Heusch, A., Henrich, B., MacKenzie, C. R., Schmidt, K. G., Schroten, H.
(2005). Acute Hemorrhagic Pericarditis in a Child with Pneumonia Due to Chlamydophila pneumoniae. J. Clin. Microbiol.
43: 520-522
[Abstract]
[Full Text]
-
Klein, M., Kotz, A., Bernardo, K., Kronke, M.
(2003). Detection of Chlamydia pneumoniae-Specific Antibodies Binding to the VD2 and VD3 Regions of the Major Outer Membrane Protein. J. Clin. Microbiol.
41: 1957-1962
[Abstract]
[Full Text]
-
Paldanius, M., Bloigu, A., Leinonen, M., Saikku, P.
(2003). Measurement of Chlamydia pneumoniae-Specific Immunoglobulin A (IgA) Antibodies by the Microimmunofluorescence (MIF) Method: Comparison of Seven Fluorescein-Labeled Anti-Human IgA Conjugates in an In-House MIF Test Using One Commercial MIF and One Enzyme Immunoassay Kit. CVI
10: 8-12
[Abstract]
[Full Text]
-
Hermann, C., Graf, K., Groh, A., Straube, E., Hartung, T.
(2002). Comparison of Eleven Commercial Tests for Chlamydia pneumoniae-Specific Immunoglobulin G in Asymptomatic Healthy Individuals. J. Clin. Microbiol.
40: 1603-1609
[Abstract]
[Full Text]
-
van der Ven, A. J. A. M., Hommels, M. J., Kroon, A. A., Kessels, A., Flobbe, K., van Engelshoven, J., Bruggeman, C. A., de Leeuw, P. W.
(2002). Chlamydia pneumoniae Seropositivity and Systemic and Renovascular Atherosclerotic Disease. Arch Intern Med
162: 786-790
[Abstract]
[Full Text]
-
Morre, S. A., Munk, C., Persson, K., Kruger-Kjaer, S., van Dijk, R., Meijer, C. J. L. M., van den Brule, A. J. C.
(2002). Comparison of Three Commercially Available Peptide-Based Immunoglobulin G (IgG) and IgA Assays to Microimmunofluorescence Assay for Detection of Chlamydia trachomatis Antibodies. J. Clin. Microbiol.
40: 584-587
[Abstract]
[Full Text]
-
Boman, J., Hammerschlag, M. R.
(2002). Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies. Clin. Microbiol. Rev.
15: 1-20
[Abstract]
[Full Text]
-
Stralin, K., Fredlund, H., Olcen, P., Bas, S., Vischer, T. L.
(2001). Labsystems Enzyme Immunoassay for Chlamydia pneumoniae Also Detects Chlamydia psittaci Infections. J. Clin. Microbiol.
39: 3425-3426
[Full Text]
-
Derfuss, T., Gurkov, R., Then Bergh, F., Goebels, N., Hartmann, M., Barz, C., Wilske, B., Autenrieth, I., Wick, M., Hohlfeld, R., Meinl, E.
(2001). Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain
124: 1325-1335
[Abstract]
[Full Text]
-
Tuuminen, T., Varjo, S., Ingman, H., Weber, T., Oksi, J., Viljanen, M.
(2000). Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae Immunoglobulin G and A Antibodies in a Healthy Finnish Population as Analyzed by Quantitative Enzyme Immunoassays. CVI
7: 734-738
[Abstract]
[Full Text]